Xilio Therapeutics (XLO) Cash from Investing Activities (2020 - 2026)
Xilio Therapeutics (XLO) posted Cash from Investing Activities of -$556000.0 for Q1 2026, down 485.26% sequentially from -$95000.0 in Q4 2025, and down 2427.27% YoY from $23890.6 in Q1 2025.
Xilio Therapeutics (XLO) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Cash from Investing Activities for 7 years, with the latest figure at -$556000.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 2427.27% year-over-year to -$556000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 2743.24% YoY) and the FY2025 annual result came in at -$518000.0, down 1338.89% from the prior year.
- Cash from Investing Activities retreated to -$556000.0 in Q1 2026 per XLO's latest filing, from -$95000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$6000.0 in Q4 2024 and troughed at -$771000.0 in Q2 2022.
- A 5-year average of -$286833.3 and a median of -$285000.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities surged 59.01% in 2023, then tumbled 2427.27% in 2026.
- Over 5 years, Cash from Investing Activities stood at -$509000.0 in 2022, then jumped by 37.92% to -$316000.0 in 2023, then jumped by 98.1% to -$6000.0 in 2024, then sank by 1483.33% to -$95000.0 in 2025, then plunged by 485.26% to -$556000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$556000.0, -$95000.0, and -$401000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19,000.00 |
| Jun 30, 2026 | -19,000.00 |
| Mar 31, 2026 | -556,000.00 |
| Mar 31, 2026 | -556,000.00 |
| Dec 31, 2025 | -95,000.00 |
| Dec 31, 2025 | -95,000.00 |
| Jun 30, 2025 | -401,000.00 |
| Jun 30, 2025 | -401,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Dec 31, 2024 | -6,000.00 |
| Dec 31, 2024 | -6,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2023 | -316,000.00 |
| Jun 30, 2023 | -316,000.00 |
| Mar 31, 2023 | -170,000.00 |
| Mar 31, 2023 | -170,000.00 |
| Dec 31, 2022 | -509,000.00 |
| Dec 31, 2022 | -509,000.00 |